Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;14(3):E57-E64.
doi: 10.5489/cuaj.5946. Epub 2019 Jul 23.

Management of urachal cancer: A consensus statement by the Canadian Urological Association and Genitourinary Medical Oncologists of Canada

Zineb Hamilou  1 , Scott North  2 , Christina Canil  3 , Lori Wood  4 , Sebastien Hotte  5 , Srikala S Sridhar  6 , Denis Soulières  1 , Mathieu Latour  7 , Daniel Taussky  8 , Wassim Kassouf  9 , Normand Blais  1
Affiliations

Management of urachal cancer: A consensus statement by the Canadian Urological Association and Genitourinary Medical Oncologists of Canada

Zineb Hamilou et al. Can Urol Assoc J. 2020 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr. North has been an advisory board member for Astellas; has received grants/honoraria from Astellas, Janssen, and Sanofi; and has participated in clinical trials supported by Astellas, Janssen, and Sanofi. Dr. Canil has been an advisory board member for AstraZeneca, Bayer, BMS, Eisai, Janssen, Merck, Novartis, and Pfizer; has received travel grants from Amgen and Sanofi; has received consulting honoraria from Janssen; and has participated in clinical trials supported by Astellas, AstraZeneca, Eisai, Janssen, and Roche. Dr. Wood has been an advisory board member (with no compensation) for Astellas, Pfizer, and Novartis; and has participated in clinical trials supported by Aragon, AstraZeneca, BMS, Exelixis, Merck, Pfizer, and Roche. Dr. Hotte has been an advisory board member for AstraZeneca, BMS, Merck, and Pfizer; and has participated in clinical trials supported by AstraZeneca, BMS, Merck, and Takeda. Dr. Sridhar has attended advisory boards for Astellas; has received grants/honoraria from Astellas, Janssen, and Sanofi; and has participated in clinical trials for Agenisys, Imclone, OGX, Roche, and Sanofi Aventis. Dr. Soulières has been an advisory board member for Novartis and Pfizer; and has participated in clinical trials supported by Merck and Pfizer. Dr. Latour received a grant for a PD1 study in urothelial carcinoma from Roche. Dr. Taussky has received honoraria from Bayer and Sanofi. Dr. Kassouf has received grants/honoraria from Amgen, Astellas, and Janssen. Dr. Blais has received consultancy fees from AstraZeneca, Bayer, BI, BMS, Merck, Novartis, Pfizer, Roche, Sanofi, and Servier. Dr. Hamilou reports no competing personal or financial interests related to this work.

References

    1. Begg RC. The urachus: Its anatomy, histology, and development. J Anat. 1930;64:170–83. - PMC - PubMed
    1. Centre for Evidence-based Medicine. Oxford Centre for Evidence-based Medicine – Levels of evidence. Mar, 2009. [Accessed Jan. 2019]. Available at: http://www.cebm.net/index.aspx?o=1025.
    1. Mylonas KS, O’Malley P, Ziogas IA, et al. Malignant urachal neoplasms: A population-based study and systematic review of literature. Urol Oncol. 2017;35:33.e11–9. doi: 10.1016/j.urolonc.2016.07.021. - DOI - PubMed
    1. Szarvas T, Modos O, Niedworok C, et al. Clinical, prognostic, and therapeutic aspects of urachal carcinoma — a comprehensive review with meta-analysis of 1010 cases. Urol Oncol. 2016;34:388–98. doi: 10.1016/j.urolonc.2016.04.012. - DOI - PubMed
    1. Peugniez C, Ghoneim T, Leroy X, et al. [Urachal cancers]. Bull Cancer. 2013;100:509–17. doi: 10.1684/bdc.2013.1718. - DOI - PubMed

LinkOut - more resources